Disclosure of total number of voting rights and number of shares in the capital as of February 28th, 2021, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
Median Technologies announced today that Fredrik Brag, CEO and founder of Median Technologies, will provide a company update on March 9th, 2021 at 11:30 am CET during a webcast.
These two appointments follow a series of first successful achievements for iBiopsy® in 2020 and early 2021. Median prepares to launch its iBiopsy® product development plan, including regulatory aspects, define its go-to-market strategy then expand its iBiopsy® operations globally.
Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide. First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021.
To download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]